Pembrolizumab with axitinib for untreated advanced renal cell carcinoma – Appraisal Consultation Document

DRAFT NICE guidance does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults as the cost-effectiveness estimates were higher than what NICE normally considers an acceptable use of NHS resources.

National Institute for Health and Care Excellence